Abbott Laboratories (ABT) Stock Analysis
Falling Knife setup
Healthcare · Medical Devices
Sell if holding. Momentum 1.0/10 is below the 5.0 floor at $89.89 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Geographic: international sales (61.0%); Weak overall score: 4.9/10.
Abbott Laboratories discovers, manufactures, and sells diversified healthcare products across four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices — serving over 160 countries with approximately 115,000 employees. No... Read more
Sell if holding. Momentum 1.0/10 is below the 5.0 floor at $89.89 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Geographic: international sales (61.0%); Weak overall score: 4.9/10. Chart setup: Death cross, below all MAs, RSI 28, MACD bearish. Score 4.9/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.60, earnings proximity 75d clear, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicinternational sales61%10-K Item 1A: 'As a global healthcare company with sales outside of the U.S. making up approximately 61 percent of Abbott's net sales in 2025'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 1.0/10 is below the 5.0 floor at $89.89 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Geographic: international sales (61.0%); Weak overall score: 4.9/10. Chart setup: Death cross, below all MAs, RSI 28, MACD bearish. Prior stop was $86.47. Score 4.9/10, moderate confidence.
Take-profit target: $106.78 (+18.7% upside). Prior stop was $86.47. Stop-loss: $86.47.
Concentration risk — Geographic: international sales (61.0%); Weak overall score: 4.9/10; Weak growth.
Abbott Laboratories trades at a P/E of 25.4 (forward 15.0). TrendMatrix value score: 6.3/10. Verdict: Sell.
35 analysts cover ABT with a consensus score of 4.0/5. Average price target: $119.
What does Abbott Laboratories do?Abbott Laboratories discovers, manufactures, and sells diversified healthcare products across four segments:...
Abbott Laboratories discovers, manufactures, and sells diversified healthcare products across four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices — serving over 160 countries with approximately 115,000 employees. No single customer is material; international sales represent approximately 61% of net sales in 2025.